Evidence map›Paper›PMID 26369953›Full record

ArticleMicrobial cell factories2015

Growth-rate dependency of de novo resveratrol production in chemostat cultures of an engineered Saccharomyces cerevisiae strain.

Tim Vos, Pilar de la Torre Cortés, Walter M van Gulik, Jack T Pronk, Pascale Daran-Lapujade

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Deorphanizing solute carriers inFrontiers in microbiology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Methanol Production by "Applied and environmental microbiology · 2020
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Selection of PofFrontiers in microbiology · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tim VosDepartment of Biotechnology, Delft University of Technology, Julianalaan 67, 2628 BC, Delft, The Netherlands. t.vos@tudelft.nl.
Pilar de la Torre CortésDepartment of Biotechnology, Delft University of Technology, Julianalaan 67, 2628 BC, Delft, The Netherlands. p.delatorre@tudelft.nl.
Walter M van GulikDepartment of Biotechnology, Delft University of Technology, Julianalaan 67, 2628 BC, Delft, The Netherlands. w.m.vangulik@tudelft.nl.
Jack T PronkDepartment of Biotechnology, Delft University of Technology, Julianalaan 67, 2628 BC, Delft, The Netherlands. j.t.pronk@tudelft.nl.
Pascale Daran-LapujadeDepartment of Biotechnology, Delft University of Technology, Julianalaan 67, 2628 BC, Delft, The Netherlands. p.a.s.daran-lapujade@tudelft.nl.
Delft University of Technology · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSaccharomyces cerevisiae has become a popular host for production of non-native compounds. The metabolic pathways involved generally require a net input of energy. To maximize the ATP yield on sugar in S. cerevisiae, industrial cultivation is typically performed in aerobic, sugar-limited fed-batch reactors which, due to constraints in oxygen transfer and cooling capacities, have to be operated at low specific growth rates. Because intracellular levels of key metabolites are growth-rate dependent, slow growth can significantly affect biomass-specific productivity. Using an engineered Saccharomyces cerevisiae strain expressing a heterologous pathway for resveratrol production as a model energy-requiring product, the impact of specific growth rate on yeast physiology and productivity was investigated in aerobic, glucose-limited chemostat cultures.

resultsStoichiometric analysis revealed that de novo resveratrol production from glucose requires 13 moles of ATP per mole of produced resveratrol. The biomass-specific production rate of resveratrol showed a strong positive correlation with the specific growth rate. At low growth rates a substantial fraction of the carbon source was invested in cellular maintenance-energy requirements (e.g. 27 % at 0.03 h(-1)). This distribution of resources was unaffected by resveratrol production. Formation of the by-products coumaric, phloretic and cinnamic acid had no detectable effect on maintenance energy requirement and yeast physiology in chemostat. Expression of the heterologous pathway led to marked differences in transcript levels in the resveratrol-producing strain, including increased expression levels of genes involved in pathways for precursor supply (e.g. ARO7 and ARO9 involved in phenylalanine biosynthesis). The observed strong differential expression of many glucose-responsive genes in the resveratrol producer as compared to a congenic reference strain could be explained from higher residual glucose concentrations and higher relative growth rates in cultures of the resveratrol producer.

conclusionsDe novo resveratrol production by engineered S. cerevisiae is an energy demanding process. Resveratrol production by an engineered strain exhibited a strong correlation with specific growth rate. Since industrial production in fed-batch reactors typically involves low specific growth rates, this study emphasizes the need for uncoupling growth and product formation via energy-requiring pathways.

Indexed as

Metabolic EngineeringBiomassBioreactorsGene Expression Regulation, FungalMetabolic Networks and PathwaysResveratrolRNA, MessengerSaccharomyces cerevisiaeStilbenesResveratrolRNA, MessengerStilbenes

Identifiers

PMID26369953
PMCPMC4570684
OpenAlexW2106970622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.